British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 4 , Pages 259-267 , June 2009

Role of PET/CT in maxillo-facial surgery

  • Wai Lup Wong

      Affiliations

    • Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood HA6 2RN, United Kingdom
    • ,
  • Vincent Batty

      Affiliations

    • Departments of Nuclear Medicine and Radiology, Southampton University Hospitals, Tremona Road, Southampton SO16 6YD, United Kingdom
    • Corresponding Author InformationCorresponding author.

,Accepted 3 November 2008.

References 

  1. Feliu AL. The role of chemistry in positron emission tomography. J Chem Educ. 1998;55–60
  2. Schmitz R, Alessio A, Kinahan P. The physics of PET/CT scanners. In:  Lin EC,  Alavi A editor. PET and PET a clinical guide. New York: Thieme; 2005;p. 3–14
  3. Beresford M, Lyburn I, Sangera B, Makris A, Wong WL. Serial integrated 18F fluoro-deoxythymidine PET CT monitoring chemotherapeutic response in invasive ductal cancer. Breast J. 2007;13:424–425
  4. Wong WL, Saunders M. Role of FDG PET in the management of head and neck squamous cell cancer. Clin Oncol. 1998;10:361–366
  5. Menda Y, Graham M. 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med. 2005;35:214–219
  6. Johansen J, Eigtved A, Buchwald C, Theilgaard S, Hansen H. Implication of FDG PET on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope. 2002;112:2009–2014
  7. Jungehulsing M, Klemens S, Damm M, et al. FDG PET is a sensitive tool for the detection of occult primary cancer (cancer of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. 2000;123:294–301
  8. Schipper JH, Schrade M, Artweiler D, Muller S, Schiuk J. PET to locate primary tumour in patients with cervical lymph node metastases from an occult tumour. HNO. 1996;44:254–257
  9. Bohusavizki KH, Klutman S, Sonnemann U, et al. F-18 FDG PET zur detection des okkulten Primartumors bei Patienten mit Lymphnotenmetastasen der Halsregion. Laryngo-Rhino-Otol. 1999;78:445–449
  10. Braams JW, Prium J, Kole AC, et al. Detection of unknown primary head and neck tumours by PET. Int J Oral Maxillofac Surg. 1997;26:112–115
  11. Safa AA, Tran LM, Rege S, et al. The role of PET in occult primary head and neck cancers. Cancer J Sci Am. 1999;5:214–218
  12. Regelink G, Brouwer J, deBree R, et al. Detection of unknown primary tumours and distant metastases in patients with cervical nodes: value of FDG PET versus conventional studies. Eur J Nucl Med. 2002;29:1024–1030
  13. Fogarty GB, Peters LJ, Stewart j , Scott C, Rischin D, Hicks RD. The usefulness of fluorine 18-labelled deoxyglucose PET in the investigation of patients with cervical lymphadenopathy from an unknown primary tumour. Head Neck. 2003;25:138–145
  14. Stoeckli SJ, Mosna-Firlejczyk K, Goerres GW. Lymph node metastases of SCC from an unknown primary: impact of PET. Eur J Nucl Med. 2003;30:411–416
  15. Gutzeit A, Antoch G, Kulh H, et al. Unknown primary tumours: detection with dual PET/CT-initial experience. Radiology. 2005;234:227–234
  16. Wong WL, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, Lemon C, Farrell R, Saunders M. Assessment of patients with occult primary head and neck cancers – an FDG PET/CT study. Acta Otolaryngol, in press.
  17. Wong WL, Gibson D, Sanghera B, Goodchild K, Saunders M. Evaluation of normal FDG uptake in palatine tonsil and its potential value for detecting occult head and neck cancers: a PET CT study. Nucl Med Commun. 2007;28:675–680
  18. Brouwer J, de Bree R, Comans EFJ, Castellijns JA, Hoekstra OS, Leeman CE. Pet using FDG in the clinically negative neck; is it likely to be superior. Eur Arch Oto-Laryngol. 2004;261:479–483
  19. Hyde NC, Prvulovich E, Newman L, Waddington WA, Visvikis D, Ell P. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and PET. Oral Oncol. 2003;39:350–360
  20. Basu D, Siegel BA, McDonald , Nussenbaum B. Detection of occult bone metastases from head and neck squamous cell cancer. Arch Otoloaryngol Head Neck Surg. 2007;113:801–805
  21. Fleming AJ, Smith S, Paul CM, et al. Impact of FDG PET CT on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–1179
  22. Keyes JW, Chen MYM, Watson NE, Greven KM, McGuirt WF, Williams DW. FDG PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck. 2000;22:105–110
  23. Frank DK, Hu KS, Culliney BE, et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope. 2005;115:1015–1020
  24. Clayman GL, Johnson CJ, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg. 2001;127:135–139
  25. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer. Head Neck. 2003;25:791–798
  26. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of PET for the detection of disease in residual neck nodes after chemo radiotherapy in head and neck cancer. Head Neck. 2005;27:175–181
  27. McCullom DA, Burrell SC, Haddad RI, et al. PET with 18F-FDG to predict pathological response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890–896
  28. Andrade RS, Heron DE, Degirmenci B, et al. Post treatment assessment of response to treatment using FDG PET CT for patients treated with definitive radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2006;1315–1322
  29. Rogers JW, Greven KM, McGuirt FW, et al. Can post RT neck dissection be omitted for patients with head and neck cancer who have a negative PET scan after definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2004;58:694–697
  30. Ong SC, Schroder H, Lee NY, et al. Clinical utility of FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532–540
  31. Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol. 2003;5:257–270
  32. Saluan PY, Abgral R, Querellou S, et al. Does 18-fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?. Head Neck. 2007;29:1115–1120
  33. Lowe VJ, Boyd JH, Dunphy FR, Kim H. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol. 2000;18:651–658
  34. Lee JC, Kim JS, Lee JH, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007;43:686–692
  35. Wood K, Wong WL, Saunders M. [64Cu]diacetyl-bis (N4-methyl-thiosemicarbazone) – a radiotracer for tumour hypoxia. Nucl Med Biol. 2008;35:393–400

PII: S0266-4356(08)00580-9

doi: 10.1016/j.bjoms.2008.11.011

British Journal of Oral and Maxillofacial Surgery
Volume 47, Issue 4 , Pages 259-267 , June 2009

Article Tools

* Image Usage & Resolution